UPDATE: Canaccord Genuity Decreases PT on Delcath Systems to $5
According to a research report this morning, Canaccord Genuity decreases its PT on Delcath Systems (NASDAQ: DCTH) from $8 to $5.
Canaccord Genuity explained, ‘These physicians provided an interesting perspective about how CHEMOSAT fits in the oncology armamentarium. We reduce our forward estimates and price target – to $5.00 from $8.00 – to reflect dilution related to the recent equity offering and previously announced delay of the NDA filing (mid-August-E).”
Delcath Systems closed Friday at $1.44 as Canaccord Genuity maintains its Buy rating.
Latest Ratings for DCTH
|May 2013||JMP Securities||Downgrades||Market Outperform||Market Perform|
|May 2013||Roth Capital||Downgrades||Buy||Sell|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.